Cecilie Maria Madsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cecilie Maria Madsen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Anette Müllertz
Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark; Bioneer A/S, Kogle Allé 2, Hørsholm 2970, Denmark
4 shared publications - Thomas Rades
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
4 shared publications - Ben J. Boyd
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, VIC 3052, Australia
2 shared publications - Camilla Foged
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen Ø, Denmark.
2 shared publications - Dennis Christensen
Department of Infectious Disease Immunology Statens Serum Institut Artillerivej 5 Copenhagen S 2300 Denmark
2 shared publications - Fabrice Rose
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications
Latest Publications
- 31 May 2017
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 14 (7) , 2294-2306
Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA
Synthetic mycobacterial cord factor analogues, e.g., trehalose 6,6′-dibehenate (TDB), are highly promising adjuvants due to their strong immunopotentiating capabilities, but their biophysical properties have remained poorly characterized. Here, we report the synthesis of an array of synthetic TDB analogues varying in acyl chain length, degree of acylation, and headgroup display, which was subjected to biophysical characterization of neat nondispersed self-assembled nanostructures in excess buffer and as aqueous dispersions with cationic dimethyldioctadecylammonium (DDA) bromide. The array comprised trehalose mono- (TMX) and diester (TDX) analogues with symmetrically shortened acyl chains [denoted by X: arachidate (A), stearate (S), palmitate (P), myristate (Myr), and laurate (L)] and an analogue with a short hydrophilic polyethylene glycol (PEG) linker inserted between the trehalose headgroup of TDS and the acyl chains (PEG-TDS). All dispersions were liposomes, but in contrast to the colloidally stable and highly cationic TDX-containing liposomes, the zeta-potential was significantly reduced for DDA/TMX and DDA/PEG-TDS liposomes, suggesting a charge-shielding effect, which compromises the colloidal stability. An increased d-spacing was observed for the lamellar phase of neat TDB analogues in excess buffer (TDS < TMS < PEG-TDS), confirming that the charge shielding is caused by an extended molecular configuration of the more flexible headgroup. Differential scanning calorimetry showed highly cooperative phase transitions for all tested dispersions albeit the monoesters destabilized the lipid bilayers. Langmuir experiments demonstrated that incorporation of TDXs and PEG-TDS stabilized DDA monolayers due to improved hydrogen bonding and reduced intermolecular repulsions. In conclusion, data suggest that the DDA/TDS dispersions exhibit favorable physicochemical properties rendering these DDA/TDS liposomes an attractive vaccine adjuvant, and they emphasize that not only the receptor binding and immune activation but also the biophysical properties of immunopotentiator formulations should be collectively considered when designing adjuvants with optimal safety, efficacy, and storage stability.
- 31 May 2017
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 14 (7) , 2294-2306
Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA
Synthetic mycobacterial cord factor analogues, e.g., trehalose 6,6′-dibehenate (TDB), are highly promising adjuvants due to their strong immunopotentiating capabilities, but their biophysical properties have remained poorly characterized. Here, we report the synthesis of an array of synthetic TDB analogues varying in acyl chain length, degree of acylation, and headgroup display, which was subjected to biophysical characterization of neat nondispersed self-assembled nanostructures in excess buffer and as aqueous dispersions with cationic dimethyldioctadecylammonium (DDA) bromide. The array comprised trehalose mono- (TMX) and diester (TDX) analogues with symmetrically shortened acyl chains [denoted by X: arachidate (A), stearate (S), palmitate (P), myristate (Myr), and laurate (L)] and an analogue with a short hydrophilic polyethylene glycol (PEG) linker inserted between the trehalose headgroup of TDS and the acyl chains (PEG-TDS). All dispersions were liposomes, but in contrast to the colloidally stable and highly cationic TDX-containing liposomes, the zeta-potential was significantly reduced for DDA/TMX and DDA/PEG-TDS liposomes, suggesting a charge-shielding effect, which compromises the colloidal stability. An increased d-spacing was observed for the lamellar phase of neat TDB analogues in excess buffer (TDS < TMS < PEG-TDS), confirming that the charge shielding is caused by an extended molecular configuration of the more flexible headgroup. Differential scanning calorimetry showed highly cooperative phase transitions for all tested dispersions albeit the monoesters destabilized the lipid bilayers. Langmuir experiments demonstrated that incorporation of TDXs and PEG-TDS stabilized DDA monolayers due to improved hydrogen bonding and reduced intermolecular repulsions. In conclusion, data suggest that the DDA/TDS dispersions exhibit favorable physicochemical properties rendering these DDA/TDS liposomes an attractive vaccine adjuvant, and they emphasize that not only the receptor binding and immune activation but also the biophysical properties of immunopotentiator formulations should be collectively considered when designing adjuvants with optimal safety, efficacy, and storage stability.
- 1 October 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (10) , 3021-3029
Studying the Propensity of Compounds to Supersaturate: A Practical and Broadly Applicable Approach
- 1 October 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (10) , 3021-3029
Studying the Propensity of Compounds to Supersaturate: A Practical and Broadly Applicable Approach
- 1 September 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (9) , 2864-2872
Interlaboratory Validation of Small-Scale Solubility and Dissolution Measurements of Poorly Water-Soluble Drugs
- 1 September 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (9) , 2864-2872
Interlaboratory Validation of Small-Scale Solubility and Dissolution Measurements of Poorly Water-Soluble Drugs
- 1 August 2016
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 91, 31-39
Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors
- 1 August 2016
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 91, 31-39
Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors